Proteomics & Protein Research

The funds will support a multi-center clinical study investigating the test's usefulness in diagnosing elderly patients with lower respiratory tract infections.

The upgrade follows four consecutive quarters of above-industry-average revenue growth, driven by the biopharma end market, and the addition of a new CEO.

The collaboration is focused on using Biognosys' HRM mass spec technology to facilitate Biodesix's companion diagnostic work.

The company posted second quarter revenues of $494.7 million, up from $481.8 million in Q2 2014 and beating the average Wall Street estimate of $481.7 million.

The five-year grant will support optimizing the use of polymyxin B to treat Gram-negative bacterial infections and identify protein biomarkers of drug-associated toxicity.